| Methods |
3‐week placebo run‐in; inclusion criteria= sitting DBP 91‐105 mm Hg after run‐in; 12‐week double‐blind treatment |
| Participants |
Valsartan 80 mg: n=63(28 males,35 females); mean age=57.4(10.8) years; baseline sitting SBP=163.9(12.5) mm Hg, DBP=97.2(5.2) mm Hg, HR=72.2(6.1) bpm;
Placebo: n=60(33 males,27 females); mean age=58.8(11.1) years; baseline sitting SBP=167.0(14.1) mm Hg, DBP=98.5(3.4) mm Hg, HR=73.6(7.9) bpm |
| Interventions |
Valsartan 80 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP;
Mean change from baseline in trough sitting HR |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; baseline SD reported; BP data from Table 3, p. 275; BP measurement device not reported; Jadad score=2; funding source= Novartis Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
